At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SGMT Sagimet Biosciences Inc.
Post-Mkt 01-14 18:59:39 EST
6.37
+0.16
+2.58%
盘后6.36
-0.01-0.16%
17:51 EST
High6.38Low6.15Vol697.64K
Open6.20D1 Closing6.21Amplitude3.70%
Mkt Cap207.16MTradable Cap144.13MTotal Shares32.52M
T/O4.39MT/O Rate3.08%Tradable Shares22.63M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Sagimet Biosciences: Advancing FASN Inhibitor Pipeline and Multi-Indication Opportunities Support Buy Rating and $26 Target
TIPRANKS  ·  01-10
Sagimet Biosciences: Advancing FASN Inhibitor Pipeline and Multi-Indication Opportunities Support Buy Rating and $26 Target
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
GlobeNewswire  ·  01-08
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
Sagimet Biosciences Reports Positive Phase 1 Results for Denifanstat and Resmetirom Combination in MASH
Reuters  ·  2025-12-18
Sagimet Biosciences Reports Positive Phase 1 Results for Denifanstat and Resmetirom Combination in MASH
Sagimet Biosciences Inc - Plans Phase 2 Trial for Mash With F4 Fibrosis
THOMSON REUTERS  ·  2025-12-18
Sagimet Biosciences Inc - Plans Phase 2 Trial for Mash With F4 Fibrosis
Sagimet Biosciences Inc - Combination Well-Tolerated With No Serious Adverse Events
THOMSON REUTERS  ·  2025-12-18
Sagimet Biosciences Inc - Combination Well-Tolerated With No Serious Adverse Events
Sagimet Biosciences Inc - Phase 2 Trial to Start in 2H 2026
THOMSON REUTERS  ·  2025-12-18
Sagimet Biosciences Inc - Phase 2 Trial to Start in 2H 2026
Sagimet Biosciences Announces Positive Results From the Phase 1 Pk Clinical Trial of Denifanstat and Resmetirom Combination
THOMSON REUTERS  ·  2025-12-18
Sagimet Biosciences Announces Positive Results From the Phase 1 Pk Clinical Trial of Denifanstat and Resmetirom Combination
Sagimet Biosciences Shares Rise on Licensing Agreement With Teva
Dow Jones  ·  2025-12-18
Sagimet Biosciences Shares Rise on Licensing Agreement With Teva
Sagimet Biosciences Secures Global License for Innovative Resmetirom API from TAPI
Reuters  ·  2025-12-17
Sagimet Biosciences Secures Global License for Innovative Resmetirom API from TAPI
Sagimet Biosciences and Tapi Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
THOMSON REUTERS  ·  2025-12-17
Sagimet Biosciences and Tapi Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
Sagimet Biosciences - Trial of Combination of Denifanstat & Resmetirom Is Underway With Topline Data Anticipated by 2025 End
THOMSON REUTERS  ·  2025-12-17
Sagimet Biosciences - Trial of Combination of Denifanstat & Resmetirom Is Underway With Topline Data Anticipated by 2025 End
BRIEF-Sagimet’S License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat
Reuters  ·  2025-12-10
BRIEF-Sagimet’S License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat
Sagimet Biosciences Inc - Grants Exclusive License to Denifanstat for China to Ascletis
THOMSON REUTERS  ·  2025-12-10
Sagimet Biosciences Inc - Grants Exclusive License to Denifanstat for China to Ascletis
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
THOMSON REUTERS  ·  2025-12-10
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
Sagimet Biosciences Grants Stock Options to New Employees
Reuters  ·  2025-12-10
Sagimet Biosciences Grants Stock Options to New Employees
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  2025-12-10
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Buy Rating for Sagimet Biosciences: Promising Pipeline Developments and Strong Financial Position
TIPRANKS  ·  2025-11-29
Buy Rating for Sagimet Biosciences: Promising Pipeline Developments and Strong Financial Position
Executive Chairman George Kemble Reports Sale of Sagimet Biosciences Inc. Common Shares
Reuters  ·  2025-11-22
Executive Chairman George Kemble Reports Sale of Sagimet Biosciences Inc. Common Shares
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
GlobeNewswire  ·  2025-11-20
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
Sagimet Biosciences Is Maintained at Market Outperform by Citizens
Dow Jones  ·  2025-11-14
Sagimet Biosciences Is Maintained at Market Outperform by Citizens

Introduction

Company Name.
Sagimet Biosciences Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Issue price:
--